Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate

Rheumatoid Arthritis Clinical Trial

— DOPPLER  

Official title:

Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate: an Interventional, Multicenter, Prospective, Open-label, Single-arm Clinical Trial With Clinical, Ultrasound and Biomarker Assessments

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05121298
• Other study ID #: CRB20-024
• Status: Recruiting
• Phase: Phase 3
• Start date: January 12, 2021
• Est. completion date: September 30, 2024

Study information

• Verified date: November 2021
• Source: Nagasaki University
• Contact: Atsushi Kawakami, MD, PhD
• Phone: +81-95-819-7260
• Email: atsushik[@]nagasaki-u.ac.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The administration of Janus kinase (JAK) inhibitors as well as biological disease-modifying anti-rheumatic drugs has dramatically improved even the clinical outcomes in rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX). Upadacitinib is a selective JAK1 inhibitor to be approved for use in RA. Nearly half of patients added JAK inhibitors including upadacitinib can achieve clinical remission in RA patients with inadequate response to MTX. As the next step, it is the great issue whether disease activity can be maintained in good condition even if MTX is discontinued after achieving clinical remission in patients treated with the combination of JAK inhibitors and MTX. Thus, it is desirable to investigate the maintenance of clinical non-relapse after discontinuation of MTX in RA patients with clinical remission during treatment with upadacitinib plus MTX. In this study, we will evaluate the proportion of patients who maintained nonclinical relapse after discontinuation of MTX in patients with RA who achieved clinical remission after treatment with upadacitinib plus MTX. We will also use musculoskeletal ultrasound (MSUS) assessments to determine whether discontinuation of MTX can be maintained nonclinical relapse in RA patients achieving clinical remission.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 155
• Est. completion date: September 30, 2024
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Patients must meet all of the following requirements to be considered for entry into

the study:

1. =20 years old

2. with the diagnosis of RA based on the American College of Rheumatology (ACR) /EULAR 2010 RA Classification Criteria

3. with at least moderate DAS28-CRP >3.2 at the eligibility evaluation

4. with at least one PD score positive joint of 22 joints examined MSUS at the eligibility evaluation

5. treated with MTX for =8 weeks prior to the providing consent, including 4 weeks or more at the same doses of 6 to 16 mg per week

6. ability and willingness to provide written informed consent and comply with the requirements of the study protocol.

Exclusion Criteria:

• The exclusion criteria are as follows:

(1) concurrent use of a corticosteroid equivalent to >7.5 mg/day of prednisolone (2) applicable an item for the contraindication of upadacitinib (3) a previous use of a JAK inhibitor (4) treatment with a corticosteroid and change of dose within 4 weeks prior to the providing consent (5) treatment with a csDMARD except MTX within 2 weeks prior to the providing consent; (6) treatment with a biologic DMARD or a biosimilar DMARD (ie, infliximab, biosimilar of infliximab, adalimumab, golimumab, certolizumab pegol, tocilizumab, sarilumab or abatacept) within 8 weeks prior to the providing consent (7) treatment with a TNF inhibitor (ie, etanercept or biosimilar of etanercept) within 4 weeks prior to the providing consent (8) use of a prohibited drug or therapy, other than the agents noted above, within 4 weeks prior to the providing consent (9) a complication causing musculoskeletal disorders other than RA (ie, ankylosing spondyloarthritis, reactive arthritis, psoriatic arthritis, crystal-induced arthritis, systemic lupus erythematosus, systemic scleroderma, inflammatory myopathy, or mixed connective tissue disease) (10) current pregnancy, breastfeeding, or noncompliant with a medically approved contraceptive regimen during and 12 months after the study period (11) inappropriateness for inclusion in this study as determined by the investigator

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Biomarker
• Musculoskeletal Ultrasound
• Rheumatoid Arthritis

Intervention

Drug:
• upadacitinib 15mg/day
Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) =3.2 at 12 weeks, and a DAS28-CRP of <2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.

Locations

Country	Name	City	State
Japan	Nagasaki University Hospital	Nagasaki

Sponsors (2)

Lead Sponsor	Collaborator
Atsushi Kawakami	AbbVie GK.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maintenance of DAS28-CRP <=3.2 from week 24 to 48 in patients who achieve the DAS28-CRP <2.6 at week 24.		at week 48
Secondary	achievement of DAS28-CRP <=3.2		at weeks 12, 24 and 36
Secondary	achievement of DAS28-CRP <2.6		at weeks 12, 24, 36 and 48
Secondary	clinical relapse (DAS28-CRP >3.2) at week 48 in patients who achieve the DAS28-CRP <2.6 at week 24		at week 48
Secondary	achievement of EULAR moderate response		at week 12
Secondary	changes in the DAS28-CRP value	Higher scores mean a more active RA.	from baseline to weeks 12, 24, 36, and 48
Secondary	changes in the DAS28-ESR value	Higher scores mean a more active RA.	from baseline to weeks 12, 24, 36, and 48
Secondary	changes in the DAS28-CRP value	Higher scores mean a more active RA.	from week 24 to weeks 36 and 48
Secondary	changes in the DAS28-ESR value	Higher scores mean a more active RA.	from week 24 to weeks 36 and 48
Secondary	changes in the clinical disease activity index (CDAI) value	Higher scores mean a more active of RA.	from baseline to weeks 12, 24, 36, and 48
Secondary	changes in the simplified disease activity index (SDAI) value	Higher scores mean a more active of RA.	from baseline to weeks 12, 24, 36, and 48
Secondary	changes in the clinical disease activity index (CDAI) value	Higher scores mean a more active of RA.	from week 24 to weeks 36 and 48
Secondary	changes in the simplified disease activity index (SDAI) value	Higher scores mean a more active of RA.	from week 24 to weeks 36 and 48
Secondary	achievement of CDAI <=2.8		at weeks 12, 24, 36 and 48
Secondary	achievement of SDAI <=3.3		at weeks 12, 24, 36 and 48
Secondary	changes in the serum levels of biomarkers	We analyze the serum levels of multiple biomarkers such as cytokines and chemokines.	from baseline to weeks 12, 24, 36, and 48
Secondary	changes in the serum levels of biomarkers	We analyze the serum levels of multiple biomarkers such as cytokines and chemokines.	from week 24 to weeks 36 and 48
Secondary	changes in the total power Doppler (PD) score	The minimum: 0, max: 66. Higher scores mean a more active RA.	from baseline to weeks 12, 24, 36, and 48
Secondary	changes in the total grayscale (GS) score	The minimum: 0, max: 66. Higher scores mean a more active RA.	from baseline to weeks 12, 24, 36, and 48
Secondary	changes in the combined PD score	The minimum: 0, max: 66. Higher scores mean a more active RA.	from baseline to weeks 12, 24, 36, and 48
Secondary	changes in the total PD score	The minimum: 0, max: 66. Higher scores mean a more active RA.	from week 24 to weeks 36 and 48
Secondary	changes in the total GS score	The minimum: 0, max: 66. Higher scores mean a more active RA.	from week 24 to weeks 36 and 48
Secondary	changes in the combined PD score	The minimum: 0, max: 66. Higher scores mean a more active RA.	from week 24 to weeks 36 and 48
Secondary	change in van der Heijde-modified total Sharp score (vdH-mTSS)	The minimum: 0, max: 3. Higher scores mean a more joint destruction and deformity.	from baseline to weeks 12, 24, 36 and 48
Secondary	change in vdH-mTSS	Higher scores mean a more joint destruction and deformity.	from week 24 to weeks 36 and 48